Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 87, Issue 1, 2003, Pages 1-25

  Russo, Jose ^a   Lareef, M Hasan ^a   Balogh, Gabriela ^a   Guo, Shanchun ^a   Russo, Irma H ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Aneuploidy; Breast; Cancer; Estrogen receptors; Human breast epithelial cells; Oxidative metabolism

Indexed keywords

AGAR; ANTIESTROGEN; BENZO[A]PYRENE; COLLAGEN GEL; CYTOCHROME P450; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; GENOMIC DNA; METHYLCELLULOSE; MICROSATELLITE DNA; PROGESTERONE; TAMOXIFEN;

ALLELE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL STRAIN; CHROMOSOME 11; CHROMOSOME 13; CHROMOSOME 17; CHROMOSOME 17Q; CHROMOSOME 3; CHROMOSOME 3Q; CHROMOSOME ABERRATION; COLONY FORMING CELL; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; DNA MICROARRAY; DNA POLYMORPHISM; EPITHELIUM CELL; ESTROGEN METABOLISM; EXPERIMENTAL MODEL; GENOME ANALYSIS; GENOTOXICITY; HETEROZYGOSITY LOSS; HUMAN; MALIGNANT TRANSFORMATION; PHENOTYPIC VARIATION; POLYMERASE CHAIN REACTION; RECEPTOR AFFINITY; REVIEW; WESTERN BLOTTING;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0242662678     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00390-X     Document Type: Review

References (179)

1. Landis S.H., Murray T., Bolden S., Wingo P.A. CA Cancer J. Clin. 49:1999;8.
2. Pike M.C., Spicer D.V., Dahmoush L., Press M.F. Estrogens, progesterone, normal breast cell proliferation and breast cancer risk. Epidemiol. Rev. 15:1993;17-35.
3. Kelsey J.L., Gammon M.D., John E.M. Reproductive factors and breast cancer. Epidemiol. Rev. 15:1993;36-47.
4. Bernstein L., Ross R.K. Endogenous hormones and breast cancer risk. Epidemiol. Rev. 15:1993;48-65.
5. Henderson B.E., Ross R., Bernstein L. Estrogens as a cause of human cancer: the Richard, estrogens as a cause of human cancer, the Richard, estrogens as a cause of human cancer: the Richard, estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 48:1988;246-253.
6. Y.J. Topper, L. Sankaran, P. Chomczynski, P. Prosser, P. Qasba, Three stages of responsiveness to hormones in the mammary cell, in: A. Angeli, H.L. Bradlow, L. Dogliotti (Eds.), Endocrinology of the Breast: Basic and Clinical Aspects; Ann. N. Y. Acad. Sci. 464 (1986) 1-10.
7. M.E. Lippman, K.K. Huff, R. Jakesz, T. Hecht, A. Kasid, S. Bates, R.B. Dickson, Estrogens regulate production of specific growth factors in hormone-dependent human breast cancer, in: A. Angeli, H.L. Bradlow, L. Dogliotti (Eds.), Endocrinology of the Breast: Basic and Clinical Aspects; Ann. N. Y. Acad. Sci. 464 (1986) 11-16.
8. Dupont W.D., Page D.L. Menopausal estrogen replacement therapy and breast cancer. Arch. Int. Med. 151:1991;67-72.
9. Toniolo P.G. Endogenous estrogens and breast cancer risk: the case for prospective cohort studies. Environ. Health Perspect. 105:1997;587-592.
10. Greenwald P., Barolom J., Nasca P., Burnett W. Vaginal cancer after maternal treatment with synthetic estrogens. N. Engl. J. Med. 12:1971;240-390.
11. Beral V., Hannaford P., Kay C. Oral contraceptive use and malignancies of the genital tract. Results from the Royal College of General Practitioners' Oral Contraception Study. Lancet. 2:1988;1331-1335.
12. Hilakivi-Clarke L. Estrogen-regulated non-reproductive behaviors and breast cancer risk: animal models and human studies. Breast Cancer Res. Treat. 46:1997;143.
13. Davis D.L., Telang N.T., Osborne M.P., Bradlow H.I. Medical hypothesis: bifunctional genetic-hormonal pathways to breast cancer. Environ. Health Perspect. 105(Suppl. 3):1997;571-576.
14. Sonnenschein C., Soto A.M. An updated review of environmental estrogen and androgen mimics and antagonists. J. Steroid Biochem. Mol. Biol. 65:1998;143-150.
15. Price M.A., Tennant C.C., Smith R.C., Kennedy S.J., Butow P.N., Kossoff M.B., Dunn S.M. Predictors of breast cancer in women recall following screening. Aust. N. Z. J. Surg. 69:1999;639-646.
16. Couse J.F., Korach K.S. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr. Rev. 20:1999;358-417.
17. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., Greene G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 95:1998;927-937.
18. McDonnell D.P. The molecular pharmacology of SERMs. TEM. 10:1999;301-311.
19. Tsai M.J., O'Malley B.W. Molecular mechanisms of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63:1994;451-486.
20. Katzenellenbogen B.S. Dynamics of steroid hormone receptor action. Annu. Rev. Physiol. 42:1980;17-35.
21. Mosselman S., Polma J., Dijkema R. ER: identification and characterization of a novel human estrogen receptor. FEBS Lett. 392:1996;49-53.
22. Kuiper G.G.J.M., Carlsson B., Grandien K., Enmark E. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors or and. Endocrinology. 138:1997;863-870.
23. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustatsson J., Kushner P.J., Scanlan T.S. Differential ligand activation of estrogen receptors ER-alpha and ER-beta at API sites. Science. 277:1997;1508-1510.
24. Rao B.R. Isolation and characterization of an estrogen binding protein which may integrate the plethora of estrogenic actions in non-reproductive organs. J. Steroid Biochem. Mol. Biol. 65:1998;3-41.
25. Bhat R.A., Harnish D.C., Stevis P.E., Lyttle C.R., Komm B.S. A novel human estrogen receptor beta: identification and functional analysis of additional N-terminal amino acids. J. Steroid Biochem. Mol. Biol. 67:1998;233-240.
26. Y-F. Hu, I.H. Russo, J. Russo, Estrogen and human breast cancer, in: M. Matzler (Ed.), Endocrine Disruptors, Springer-Verlag, Heidelberg, 2001, pp. 1-26.
27. van Landeghem A.A.J., Poortman J., Nabuurs M., Thijssen J.H.H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 45:1985;2900-2906.
28. Labrie F. Intracrinology. Mol. Cell. Endocrinol. 78:1991;C113-C118.
29. Labrie F., Simard J., Luu-The V., Pelletier G., Belghmi K., Belanger A. Structure, regulation and role of 3 beta-hydroxysteroid dehydrogenase, 17 beta-hydroxysteroid dehydrogenase and aromatase enzymes in the formation of sex steroids in classical and peripheral intracrine tissues. Bailliere's Clin. Endocrinol. Metab. 8:1994;451-474.
30. Pasqualini J.R., Chetrite G., Nguyen B.L., Maloche C., Talbi M., Feinstein M.C., Blacker C., Botella J., Paris J. Estrone sulfate-sulfatase and 17 beta-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. J. Steroid. Biochem. Mol. Biol. 53:1995;407-412.
31. Reed M.J., Purohit A. Breast cancer and the role of cytokines in regulating estrogen synthesis: an emerging hypothesis. Endocr. Rev. 18:1997;701-715.
32. Simpson E.R., Mahendroo M.S., Means G.D., Kilgore M.W., Graham-Lorence S., Amarneh B., Ito Y., Fisher C.R., Michael M.D. Endocr. Rev. 15:1994;342.
33. Santen R.J., Santner S.J., Pauley R.J., Tait L., Kaseta J., Demers L.M., Hamilton C., Yue W., Wang J.P. Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible? J. Steroid Biochem. Mol. Biol. 61:1997;267-271.
34. Brodie A., Lu Q., Nakamura J. Aromatase in the normal breast and breast cancer. J. Steroid Biochem. Mol. Biol. 61:1997;281-286.
35. Koh J.I., Kubota T., Sasano H., Hashimotom M., Hosoda Y., Kitajima M. Stimulation of human tumor xenograft growth by local estrogen biosynthesis in stromal cells. Anticancer Res. 18:1998;2375-2380.
36. Mor G., Yue W., Santen R.J., Gutierrez L., Eliza M., Berstein L.M., Harada N., Wang J., Lysiak J., Diano S., Naftolin F. J. Steroid Biochem. Mol. Biol. 67:1998;403.
37. Miller W.R., O'Neill J. The importance of local synthesis of estrogen within the breast. Steroids. 50:1987;537-548.
38. Dowsett M. Future uses for aromatase inhibitors in breast cancer. J. Steroid Biochem. Mol. Biol. 61:1997;261-266.
39. Sasano H., Ozaki M. Aromatase expression and its localization in human breast cancer. J. Steroid Biochem. Mol. Biol. 61:1997;293-298.
40. Orentreich N., Brind J.L., Rizer R.L. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J. Clin. Endocrinol. Metab. 59:1984;551-555.
41. Falany J.L., Falany C.N. Regulation of estrogen activity by sulfation in human MCF-7 breast cancer cells. Oncol. Res. 9:1997;589-596.
42. Utsumi T., Yoshimura N., Takeuchi S., Ando J., Maruta M., Maeda K., Harada N. Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. Cancer Res. 59:1999;377-381.
43. Martel C., Rheaume E., Takahashi M., Trudel C., Couet J., Luu-The V., Simard J., Labrie F. Distribution of 17 beta-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues. J. Steroid Biochem. Mol. Biol. 41:1992;597-603.
44. Luu-The V., Zhang Y., Poirier D., Labrie F. Characteristics of human types 1, 2 and 3 17 beta-hydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition. J. Steroid Biochem. Mol. Biol. 55:1995;581-587.
45. Simard J., Durocher F., Mebarki F., Turgeon C., Sanchez R., Labrie Y., Couet J., Trudel C., Rheaume E., Morel Y., Luu-The V., Labrie F. Molecular biology and genetics of the 3 beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. J. Endocrinol. 50:1996;S189-207.
46. Sasano H., Frost A.R., Saitoh R., Harada N., Poutanen M., Vihko R., Bulun S.E., Silverberg S.G., Nagura H. Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. J. Clin. Endocrinol. Metab. 81:1996;4042-4046.
47. Miller W.R., Anderson T.J., Lack W.J.L. Relationship between tumour aromatase activity. J. Steroid Biochem. Mol. Biol. 37:1990;1055-1059.
48. Esteban J.M., Warsi Z., Haniu M., Hall P., Shively J.E., Chen S. Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation. Am. J. Pathol. 940:1992;337-343.
49. J. Russo, I.H. Russo, Role of hormones in human breast development: the menopausal breast, in: B.G. Wren (Ed.), Progress in the Management of Menopause, Parthenon Publishing, New York, 1997, p. 184.
50. Russo I.H., Russo J. Role of hormones in cancer initiation and progression. J. Mammary Gland Biol. Neoplasia. 3:1998;49-61.
51. Russo J., Russo I.H. Role of differentiation in the pathogenesis and prevention of breast cancer. Endocr. Related Cancer. 4:1997;7.
52. Calaf G., Alvarado M.E., Bonney G.E., Amfoh K.K., Russo J. Influence of lobular development on breast epithelial cell proliferation and steroid hormone receptor content. Int. J. Oncol. 7:1997;1285.
53. Russo J., Russo I.H. Influence of differentiation and cell kinetics on the susceptibility of the rat mammary gland to carcinogenesis. Cancer Res. 40:1980;2677.
54. Russo J., Russo I.H. Biological and molecular bases of mammary carcinogenesis. Lab. Invest. 57:1987;112.
55. Russo J., Rivera R., Russo I.H. Influence of age and parity on the development of the human breast. Breast Cancer Res. Treat. 23:1992;211.
56. Russo J., Grill C., Ao X., Russo I.H. Pattern of distribution for estrogen receptor α and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res. Treat. 53:1999;217-227.
57. Clark R.B.k., Howell A., Potten C.S., Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res. 57:1997;4987-4991.
58. Foster J.S., Wimalasena J. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Mol. Endocrinol. 10:1996;488-498.
59. Wang W., Smith R., Burghardt R., Safe S.H. 17 beta-estradiol-mediated growth inhibition of MDA-MB-468 cells stably transfected with the estrogen receptor: cell cycle effects. Mol. Cell. Endocrinol. 133:1997;49-62.
60. Zajchowski D.A., Sager R., Webster L. Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor. Cancer Res. 53:1993;5004-5011.
61. Calaf G., Tahin Q., Alvarado M.E., Estrada S., Cox T., Russo J. Hormone receptors and cathepsin D levels in human breast epithelial cells transformed by chemical carcinogens. Breast Cancer Res. Treat. 29:1993;169-177.
62. Santen R.J. Symposium overview. J. Natl. Cancer Inst. Monogr. 27:2000;15-16.
63. Adlercreutz H., Gorbach S.L., Goldin B.R., Woods M.N., Hamalainen E. Estrogen metabolism and excretion in Oriental and Caucasian women. J. Natl. Cancer Inst. 86:1994;1076-1082.
64. Roy D., Liehr J.G. Temporary decrease in renal quinone and reductase activity induced by chronic administration of estradiol to male Syrian hamsters-increased superoxide formation by redox cycling of estrogen. J. Biol. Chem. 263:1988;3646-3651.
65. Meads T., Schroer T.A. Polarity and nucleation of microtubules in polarized epithelial cells. Cell Motil. Cytoskeleton. 32:1995;273-288.
66. Whitehead C.M., Salisbury J.L. Regulation and regulatory activities of centrosomes. J. Cell. Biochem. Suppl. 32-33:1999;192-199.
67. Sluder G., Hinchcliffe E.H. Control of centrosome reproduction: the right number at the right time. Biol. Cell. 91:1999;413-427.
68. Pihan G.A., Doxsey S.J. The mitotic machinery as a source of genetic instability in cancer. Semin. Cancer Biol. 9:1999;289-302.
69. Brinkley B.R., Goepfert T.M. Supernumerary centrosomes and cancer: Boveri's hypothesis resurrected. Cell Motil. Cytoskeleton. 41:1998;281-288.
70. Lingle W.L., Lutz W.H., Ingle J.N., Maihle N.J., Salisbury J.L. Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity. Proc. Natl. Acad. Sci. U.S.A. 95:1998;2950-2955.
71. Mendelin J., Grayson M., Wallis T., Visscher D.W. Analysis of chromosome aneuploidy in breast cancer progression using fluorescence in situ hybridization. Lab. Invest. 79:1999;387-393.
72. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instabilities in human cancers. Nature (London). 396:1998;643-648.
73. Chakravarti D., Mailander P., Cavalieri E.L., Rogan E.G. Evidence that error-prone DNA repair converts dibenzo[a,l]pyrene-induced depurinating lesions into mutations: formation. Mutation Res. 456:2000;17-32.
74. Khan S.A., Rogers M.A., Khurana K.K., Meguid M.M., Numann P.J. Estrogen receptor expression in benign breast epithelium and breast cancer risk. J. Natl. Cancer Inst. 89:1997;3742.
75. Russo J., Reina D., Frederick J., Russo I.H. Expression of phenotypical changes by human breast epithelial cells treated with carcinogens in vitro. Cancer Res. 48:1988;2837-2857.
76. Russo J., Calaf G., Russo I.H. A critical approach to the malignant transformation of human breast epithelial cells. CRC Crit. Rev. Oncogen. 4:1993;403-417.
77. Russo J., Gusterson B.A., Rogers A.E., Russo I.H., Wellings S.R., Van Zwieten M.J. Comparative study of human and rat mammary tumorigenesis. Lab. Invest. 62:1990;1-32.
78. Harlan L.C., Coates R.J., Block G. Estrogen receptor status and dietary intakes in breast cancer patients. Epidemiology. 4:1993;25-31.
79. Habel L.A., Stanford J.L. Hormone receptors and breast cancer. Epidemiol. Rev. 15:1993;209-219.
80. Moolgavkar S.H., Day N.E., Stevens R.G. Two-stage model for carcinogenesis: epidemiology of breast cancer in females. J. Natl. Cancer Inst. 65:1980;559-569.
81. Hu Y.F., Lau K.M., Ho S.M., Russo J. Increased expression of estrogen receptor beta in chemically transformed human breast epithelial cells. Int. J. Oncol. 12:1998;1225-1228.
82. Lau K.M., Leav I., Ho S.M. Rat estrogen receptor α and β, and progesterone receptor mRNA expression in various prostatic lobes and microdissected normal and dysplastic epithelial tissues of the Noble rats. Endocrinology. 139:1998;424-427.
83. Brandenberger A.W., Tee M.K., Jaffe R.B. Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. J. Clin. Endocrinol. Metab. 83:1998;1025-1028.
84. Aronica S.M., Kraus W.L., Katzenellenbogen B.S. Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc. Natl. Acad. Sci. U.S.A. 91:1994;8517-85121.
85. Rosen J.M., Humphreys R., Krnacik S., Juo P., Raught B. The regulation of mammary gland development by hormones, growth factors, and oncogenes. Prog. Clin. Biol. Res. 387:1994;11-95.
86. Murphy L.C., Dotzlaw H., Leygue E., Coutts A., Watson P. The regulation of mammary gland development by hormones, growth factors, and oncogenes. J. Steroid Biochem. Mol. Biol. 65:1998;175-180.
87. Ball P., Knuppen R. Catecholestrogens (2- and 4-hydroxy-oestrogens). Chemistry, biosynthesis, metabolism, occurrence and physiological significance. Acta Endocrinol. (Copenh.). 232(Suppl. 1):1980;127.
88. Zhu B.T., Bui Q.D., Weisz J., Liehr J.G. Conversion of estrone to 2- and 4-hydroxyestrone by hamster kidney and liver microsomes: implications for the mechanism of estrogen-induced carcinogenesis. Endocrinology. 135:1994;1772-1779.
89. Ashburn S.P., Han X., Liehr J.G. Microsomal hydroxylation of 2- and 4-fluoroestradiol to catechol metabolites and their conversion to methyl ethers: catechol estrogens as possible mediators of hormonal carcinogenesis. Mol. Pharmacol. 43:1993;534-541.
90. Knuppen R., Ball P., Emons G. Importance of A-ring substitution of estrogens for the physiology and pharmacology of reproduction. J. Steroid Biochem. 24:1986;193-198.
91. Osborne M.P., Bradlow H.L., Wong G.Y.C., Telang N.T. Upregulation of estradiol C16 alpha-hydroxylation in human breast tissue: a potential biomarker of breast cancer risk. J. Natl. Cancer Inst. 85:1993;1917-1920.
92. Sipe H.J. Jr., Jordan S.J., Hanna P.M., Mason R.P. The metabolism of 17 beta-estradiol by lactoperoxidase: a possible source of oxidative stress in breast cancer. Carcinogenesis. 15:1994;2637-2643.
93. Malins D.C., Holmes E.H., Polissar N.L., Gunselman S.J. The etiology of breast cancer. Characteristic alteration in hydroxyl radical-induced DNA base lesions during oncogenesis with potential for evaluating incidence risk. Cancer. 71:1993;3036-3043.
94. Cavalieri E.L., Stack D.E., Devanesan P.D., Todorovic R., Dwivedy I., Higginbotham S., Johansson S.L., Patil K.D., Gross M.L., Gooden J.K., Ramanathan R., Cerny R.L., Rogan E.G. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc. Natl. Acad. Sci. U.S.A. 99:1997;10937-10942.
95. Li J.J., Li S.A. Estrogen carcinogenesis in Syrian hamster tissue: role of metabolism. Fed. Proc. 46:1987;1858-1863.
96. J. Furth, Hormones as etiological agents in neoplasia, in: F.F. Becker (Ed.), Cancer. A Comprehensive Treatise. 1. Etiology: Chemical and Physical Carcinogenesis. Plenum Press, New York, 1982, Chapter 4, pp. 89-134.
97. Li J.J., Li S.A. Estrogen carcinogenesis in hamster tissues: a critical review. Endocrinology. Rev.11:1990;524-531.
98. Li J.J. Estrogen carcinogenesis in hamster tissues: update. Endocr. Rev. 1:1993;94-95.
99. Liehr J.G. Is estradiol a genotoxic mutagenic carcinogen? Endocr. Rev. 21:2000;40-54.
100. Cavalieri E., Frenkel K., Liehr J.G., Rogan E., Roy D. Estrogens as endogenous genotoxic agents - DNA adducts and mutations. J. Natl. Cancer Inst. Monogr. 27:2000;75-93.
101. Liehr J.G. Genotoxicity of estrogens: a role in cancer development? Hum. Reprod. Update. 7:2001;1-9.
102. Rajah T.T., Pento J.T. The mutagenic potential of antiestrogens at the HPRT locus in V79 cells. Res. Commun. Mol. Pathol. Pharmacol. 89:1995;85-92.
103. Kong L.-Y., Szaniszlo P., Albrecht T., Liehr J.G. Frequency and molecular analysis of HPRT mutations induced by estradiol in Chinese hamster V79 cells. Int. J. Oncol. 17:2000;1141-1149.
104. Tsutsui T., Tamura Y., Yagi E. Involvement of genotoxic effects in the initiation of estrogen-induced cellular transformation: studies using Syrian hamster embryo cells treated with 17β-estradiol and eight of its metabolites. Int. J. Cancer. 86:2000;8-14.
105. Russo J., Hu Y.F., Tahin Q., Mihaila D., Slater C., Lareef M.H., Russo I.H. Carcinogenicity of estrogens in human breast epithelial cells. Acta Pathol. Microbiol. Immunol. Scand. (APMIS). 109:2001;39-52.
106. Thibodeau P.A., Bissonnette N., Bedard S.K., et al. Induction by estrogens of methotrexate resistance in MCF-7 breast cancer cells. Carcinogenesis. 19:1998;1545-1552.
107. Hodgson A.V., Ayala-Torres S., Thompson E.B., Liehr J.G. Estrogen-induced microsatellite DNA alterations are associated with Syrian hamster kidney tumorigenesis. Carcinogenesis. 19:1988;2169-2172.
108. Loeb L.A. A mutator phenotype in cancer. Perspect. Can. Res. 61:2001;3230-3239.
109. Boyd J., Takahashi H., Waggoner S.E., Jones L.A., Hajek R.A., Wharton J.T., Liu F.S., Fujino T., McLachlan J.A. Molecular genetics analysis of clear cell adenocarcinomas of the vagina associated and unassociated with diethylstilbestrol exposure in utero. Cancer. 77:1996;507-513.
110. Richard S.M., Bailliet G., Paez G.L., Bianchi M.S., Peltomaki P., Bianchi N.O. Nuclear and mitochondrial genome instability in human breast cancer. Cancer Res. 60:2000;4231-4237.
111. Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L., Markowitz S., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R., Minna J.D. Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers. Oncogene. 20:2001;1005-1009.
112. Piao Z., Lee K.S., Kim H., Perucho M., Malkhosyan S. Identification of novel deletion regions of chromosome arms 2q and 6p in breast carcinomas by amplotype analysis. Genes Chromosomes Cancer. 30:2001;113-122.
113. Caldes T., Perez-Segura P., Tosar A., de La Hoya M., Diaz-Rubio E. Microsatellite instability correlates with negative expression of estrogen and progesterone receptors in sporadic breast cancer. Teratogene. Carcinogen. Mutagen. 20:2000;283-291.
114. Miyazaki M., Tamaki Y., Sakita I., Fujiwara Y., Kodta M., Masuda N., Ooka M. Detection of microsatellite alterations in nipple discharge accompanied by breast cancer. Breast Cancer Res. Treat. 60:2000;35-41.
115. Ando Y., Iwase H., Ichihara S., Toyoshima S., Nakamura T., Yamashita H. Loss of heterozygosity and microsatellite instability in ductal carcinoma in situ of the breast. Cancer Lett. 156:2000;207-214.
116. Tokunaga E., Oki E., Oda S., Kataoka A., Kitamura K., Ohno S., Maehara Y., Sugimachi K. Frequency of microsatellite instability in breast cancer determined by high-resolution fluorescent microsatellite analysis. Oncology. 59:2000;44-49.
117. Shaw J.A., Smith B.M., Walsh T., Johnson S., Promrose L., Slade M.J., Walker R.A., Coombes R.C. Microsatellite alterations plasma DNA of primary breast cancer patients. Clin. Cancer Res. 6:2000;1119-1124.
118. Cavalieri E.L., Rogan E.G. The approach to understanding aromatic hydrocarbon carcinogenesis. The central role of radical cations in metabolic activation. Pharmacol. Ther. 55:1992;183-199.
119. E.L. Cavalieri, E.G. Rogan, Mechanisms of tumor initiation by polycyclic aromatic hydrocarbons in mammals, in: A.H. Neilson (Ed.), The Handbook of Environmental Chemistry: PAHs and Related Compounds, vol. 3J, Springer, Heidelberg, Germany, 1998, pp. 81-117.
120. Chakravarti D., Pelling J.C., Cavalieri E.L., Rogan E.G. Relating aromatic hydrocarbon-induced DNA adducts and c-Harvey-ras mutations in mouse skin papillomas: the role of apurinic sites. Proc. Natl. Acad. Sci. U.S.A. 92:1995;10422-10426.
121. Liehr J.G., Fang W.F., Sirbasku D.A., Ari-Ulubelen A. Carcinogenicity of catecholestrogens in Syrian hamsters. J. Steroid Biochem. 24:1986;353-356.
122. 2-3,4-quinone with DNA. Proc. Am. Assoc. Cancer Res. 39:1998;636.
123. Chakravarti D., Mailander P., Franzen J., Higginbotham S., Cavalieri E., Rogan E. Detection of dibenzo[a,l]pyrene-induced H-ras codon 61 mutant genes in preneoplastic SENCAR mouse skin using a new PCR-RFLP method. Oncogene. 16:1998;3203-3210.
124. Miller W.R., O'Neill J. The importance of local synthesis of estrogen within the breast. Steroids. 50:1987;537-548.
125. Simpson E.R., Mahendroo M.S., Means G.D., Kilgore M.W., Hinshelwood M.M., Graham-Lorence S., et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr. Rev. 15:1994;342-355.
126. Yue W., Wang J.P., Hamilton C.J., Demers L.M., Santen R.J. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res. 58:1998;927-932.
127. Yue W., Santen R.J., Wang J.P., Hamilton C.J., Demers L.M. Aromatase within the breast. Endocr. Related Cancer. 6:1999;157-164.
128. C.R. Jefcoate, J.G. Liehr, R.J. Santen, T.R. Sutter, J.D. Yager, W. Yue, S.J. Santner, R. Tekmal, L. Demers, R. Pauley, F. Naftolin, G. Mor, L. Berstein, Tissue-specific synthesis and oxidative metabolism of estrogens, in: E. Cavalieri, E. Rogan (Eds.), JNCI Monograph 27: Estrogens as Endogenous Carcinogens in the Breast and Prostate, Oxford Press, Oxford, 2000, pp. 95-112.
129. Reed M.J., Purohit A. Breast cancer and the role of cytokines in regulating estrogen synthesis: an emerging hypothesis. Endocr. Rev. 18:1997;701-715.
130. Spink D.C., Hayes C.L., Young N.R., Christou M., Sutter T.R., Jefcoate C.R. The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on estrogen metabolism in MCF-7 breast cancer cells: evidence for induction of a novel 17β-estradiol 4-hydroxylase. J. Steroid Biochem. Mol. Biol. 51:1994;251-258.
131. Hayes C.L., Spink D.C., Spink B.C., Cao J.Q., Walker N.J., Sutter T.R. 17β-Estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc. Natl. Acad. Sci. U.S.A. 93:1996;9776-9781.
132. Spink D.C., Spink B.C., Cao J.Q., DePasquale J.A., Pentecost B.T., Fasco M.J. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis. 19:1998;291-298.
133. Badawi A.F., Devanesan P.D., Edney J.A., West W.W., Higginbotham S., Rogan E.G., Cavalieri E.L. Estrogen metabolites and conjugates: biomarkers of susceptibility to human breast cancer. Proc. Am. Assoc. Cancer Res. 42:2001;664.
134. Visscher D.W., Micale M.A., Crissman J.D. Pathological and biological relevance of cytophotometric DNA content to breast carcinoma genetic progression. J. Cell. Biochem. Suppl. 17:1993;114-122.
135. M.D. Berado, P. O'Connell, D.C. Allred, Biological characteristics of premalignant and preinvasive breast disease, in: J.R. Pasqualine, B.S. Katzenellenbogen (Eds.), Hormone-Dependent Cancer, Marcel Dekker, New York, 1996, pp. 1-23.
136. Oshimura M., Barrett J.C. Chemically-induced aneuploidy in mammalian cells: mechanisms and biological significance in cancer. Environ. Mutagen. 8:1986;129-159.
137. Aardema M.J., Crosby L.L., Gibson D.P., Kerckaert G.A., LeBoeuf R.A. Aneuploidy and consistent structural chromosome changes associated with transformation of Syrian hamster embryo cells. Cancer Genet. Cytogenet. 96:1997;140-150.
138. Aldaz C.M., Chen T., Sohin A., Cunningham J., Bondy M. Comparative allelotypes of in situ and invasive human breast cancer: high frequency of micro-satellite instability in lobular breast carcinomas. Cancer Res. 55:1995;3976-3981.
139. Pihan G.A., Doxsey S.J. The mitotic machinery as a source of genetic instability in cancer. Semin. Cancer Biol. 9:1999;289-302.
140. Mitelman F., Levan G. Clustering of aberrations on specific chromosomes in human neoplasms. A survey of 1871 cases. Hereditas. 95:1981;79-139.
141. Goepfert T.M., McCarthy M., Kittrell F.S., Stephens C., Ullrich R.L., Brinkley B.R., Medina D. Progesterone facilitates chromosome instability (aneuploidy) in p53 null normal mammary epithelial cells. FASEB J. 14:2000;2221-2229.
142. Greendale G.A., Reboussin B.A., Sie A., Singh R., Olsen L.K., Gateswood O., Bassett L.W., Wasilauskas C., Bush T., Barrett-Connor E. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann. Int. Med. 130:1999;262-269.
143. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J. Am. Med. Assoc. 283:2000;485-491.
144. Ross R.K., Paganini-Hill A., Wan P.C., Pike M.C. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J. Natl. Cancer Inst. 92:2000;328-332.
145. Fukasawa K., Choi T., Kuriyama R., Rulong S., Vande Woude G.F. Abnormal centrosome amplification in the absence of p53. Science. 271:1996;1744-1747.
146. Pihan G.A., Purohit A., Wallace J., Knecht H., Woda B., Quesenberry P., Doxsey S.J. Centrosome defects and genetic instability in malignant tumors. Cancer Res. 58:1998;3974-3985.
147. Zhou H., Kuang J., Zhong L., Juo W.-L., Gray J.W., Sahin A., Brinkley B.R., Sen S. Tumour amplified kinase STK15/BRAK induces centrosome amplification, aneuploidy and transformation. Nature (London) Genet. 20:1998;189-193.
148. Lingle W.L., Salisbury J.L. Altered centrosome structure is associated with abnormal mitoses in human breast tumors. Am. J. Pathol. 155:1999;1941-1951.
149. Trent J.M., Wiltshire R., Su L., Nicolaides N.C., Vogelstein B., Kinzler K.W. The gene for the APC-binding protein beta-catenin (CTNNB1) maps to chromosome 3p22, a region frequently altered in human malignancies. Cytogenet. Cell Genet. 71:1995;343-344.
150. Dietrich C.U., Pandis N., Teixeira M.R., Bardi G., Gerdes A.M., Andersen J.A., Heim S. Chromosome abnormalities in benign hyper-proliferative disorders of epithelial and stromal breast tissue. Int. J. Cancer. 60:1995;49-53.
151. Pennisi E. New gene forges link between fragile site and many cancers. Science. 272:1996;649.
152. Cuthbert A.P., Bond J., Trott D.A., Gill S., Broni J., Marriott A., Khoudoli G., Parkinson E.K., Cooper C.S., Newbold R.F. Telomerase repressor sequences on chromosome 3 and induction of permanent growth arrest in human breast cancer cells. J. Natl. Cancer Inst. 91:1999;37-45.
153. Negrini M., Sabbioni S., Haldar S., Possati L., Castagnoli A., Corallini A., Barbanti-Brodano G., Croce C.M. Tumor and growth suppression of breast cancer cells by chromosome 17-associated functions. Cancer Res. 54:1994;1818-1824.
154. Borresen A.L., Andersen T.I., Garber J., Barbier-Piraux N., Thorlacius S., Eyfjord J., Ottestad L., Smith-Sorensen B., Hovig E., Malkin D. Screening for germ line TP53 mutations in breast cancer patients. Cancer Res. 52:1992;3234-3236.
155. Puech A., Henry I., Jeanpierre C., Junien C. A highly polymorphic probe on 11p15.5: L22.5.2 (D11S774). Nucleic Acids Res. 19:1991;5095-5099.
156. Hannigan G.E., Bayani J., Weksberg R., Beatty B., Pandita A., Dedhar S., Squire J. Mapping of the gene encoding the integrin-linked kinase, ILK, to human chromosome 11pl5.5-pl5.4. Genomics. 42:1997;177-179.
157. 2F, cyclins and cyclin dependent kinases. Oncogene. 15:1997;143-157.
158. Dong J.-T., Lamb P.W., Rinker-Schaeffer C.W., Vukanovic J., Ichikawa T., Isaacs J.T., Barrett J. KA/1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science. 268:1995;884-886.
159. Wei Y., Lukashev M., Simon D. Regulation of integrin function by the urokinase receptor. Science. 273:1996;1551-1555.
160. Hampton G.M., Mannermaa A., Winquist R., Alavaikko M., Blanco G., Taskinen P.G., Kiviniemi H., Newsham I., Cavenee W.K., Evans G.A. Losses of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Res. 54:1994;4586-4589.
161. Negrini M., Rasio D., Hampton G.M., Sabbioni S., Rattan S., Carter S.M., Rosenberg A.L., Schwartz G.F., Shiloh Y., Cavenee W.K., Croce C.M. Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3. Cancer Res. 55:1995;3003-3007.
162. Winqvist R., Hampton G.M., Mannermaa A., Blanco G., Alavaiko M., Kiviniemi H., Taskinen P.J., Evans G.A., Wright F.A., Newsham I., Cavenee W.K. Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res. 55:1995;2660-2664.
163. Elson A., Wang Y., Daugherty C.J., Morton C.C., Zhou F., Campos-Torres J., Leder P. Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 93:1996;13084-13089.
164. Westphal C.H., Schmaltz C., Rowan S., Elson A., Fisher D.E., Leder P. Genetic interactions between atm and p53 influence cellular proliferation and irradiation-induced cell cycle checkpoints. Cancer Res. 57:1997;1664-1667.
165. Soule H.D., Maloney T.M., Wolman S.R., Peterson W.D. Jr., Brenz R., McGrath C.M., Russo J., Pauley R., Jones R.F., Brooks S.C. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 50:1990;6075-6086.
166. Tait L., Soule H., Russo J. Ultrastructural and immunocytochemical characterizations of an immortalized human breast epithelial cell line MCF-10. Cancer Res. 50:1990;6087-6099.
167. Calaf G., Russo J. Transformation of human breast epithelial cells by chemical carcinogens. Carcinogenesis. 14:1993;483-492.
168. Russo J., Calaf G., Russo I.H. A critical approach to the malignant transformation of human breast epithelial cells. CRC Crit. Rev. Oncogen. 4:1993;403-417.
169. Russo J., Lareef M.H., Tahin Q., Hu Y.-F., Slater C.M., Ao X., Russo I.H. 17 Beta estradiol is carcinogenic in human breast epithelial cells. J. Steroid Biochem. Mol. Biol. 80:2002;149-162.
170. Huang Y., Bove B., Wu Y.L., Russo I.H., Yang X., Zekri A., Russo J. Microsatellite instability during immortalization and transformation of human breast epithelial cells in vitro. Mol. Carcinogen. 24:1999;118-127.
171. Yen T.J., Li G., Schaar B., Szilak I., Cleveland D.W. CENP-E is a putative kinetochore motor that accumulates just prior to mitosis. Nature. 359:1992;536-539.
172. Johnson S.M., Shaw J.A., Walker R.A. Sporadic breast cancer in young women: prevalence of loss of heterozygosity at p53, BCRA1 and BCRA2. Int. J. Cancer. 98:2002;205-210.
173. Farabegoli F., Champeme M.H., Bieche I., Santini D., Ceccarelli C., Derenzini M., Liderau R. Genetic pathways in the evolution of breast ductal carcinoma in situ. J. Pathol. 196:2002;280-286.
174. Garcia A., Bussaglia E., Machin P., Matias-Guiu X., Prat J. Loss of heterozygosity on chromosome 17q in epithelial ovarian tumors: association with carcinomas with serous differentiation. Int. J. Gynecol. Pathol. 19:2000;152-157.
175. Plummer S.J., Paris M.J., Myles J., Tubbs R., Crowe J., Casey G. Four regions of allelic imbalance on 17q12-qter associated with high grade breast tumors. Genes Chromosomes Cancer. 20:1997;354-362.
176. Basolo F., Elliott J., Tait L., Chen X.Q., Maloney T., Russo I.H., Pauley R., Momiki S., Caamano J., Klein-Szanto A.J.P., Koszalka M., Russo J. Transformation of human breast epithelial cells by c-Ha-ras oncogene. Mol. Carcinogen. 4:1991;25-35.
177. Krege J.H., Hodgin J.B., Couse J.F. Generation and reproductive phenotypes of mice lacking oestrogen receptor β Proc. Natl. Acad. Sci. U.S.A. 95:1998;15677-15682.
178. Paech K., Webb P., Kuiper G.G.J.M., Nilsson S., Gustafsson J.A., Kushner P.J., Scanlan T.S. Science. 277:1997;1508.
179. J. Russo, I.H. Russo, Biological and Molecular Basis of Breast Cancer, Springer-Verlag, Heidelberg, Germany, 2003.